Skip to main content

Table 1 Study measures and timing

From: Protocol for the OUTREACH trial: a randomised trial comparing delivery of cancer systemic therapy in three different settings - patient's home, GP surgery and hospital day unit

 

Data point 1: Baseline, prior to commencing treatment

Data point 2: 4** weeks into treatment

Data point 3: 8** weeks into treatment

Data point 4: 12 weeks into treatment

Data point 5: 24*** weeks into treatment

Clinic Review*

x

  

x

X

PS

x

x

x

x

X

Weight

x

x

x

x

 

Blood tests*

x

    

Radiology*

x

    

EORTC QLQC30.

x

x

x

x

X

HAD, EQ-5D and Patient Satisfaction Questionnaire

x

x

x

x

X

CSRI Completion

x

  

x

 

Patient Diary for AE Recording

x

x

x

x

X

Semi-Structured Interview

x(1 in 10 patients)

  

x

 
  1. *Clinic review, blood tests and radiological investigations will be carried out according to standard clinical practice at baseline and during the study period.
  2. ** +/- 1 Week
  3. *** For patients whose treatment continues beyond 12 weeks, patients will complete a further set of trial assessments when their treatment stops or at 24 weeks, whichever is sooner. This data point is optional.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us